More Stories

Informist, Wednesday, Dec. 3, 2025

HYDERABAD - Cipla Ltd. has announced the launch of Ciplostem, an innovative stem cell therapy for knee osteoarthritis in India. The therapy was developed by Stempeutics Research and approved by the Drug Controller General of India, Cipla said in a press release. The therapy offers a disease-modifying treatment option targeting grade II and III knee osteoarthritis and marks a significant advancement in Cipla's entry into orthobiologic medicine, the company said. Cipla didn't disclose the financials of the partnership with Stempeutics Research for the Ciplostem launch.

Ciplostem is a single-dose intra-articular injection, directly injected into the knee joint, comprising 25 million ex vivo expanded, pooled, cultured adult human bone marrow-derived mesenchymal stem cells. The therapy is co-administered with hyaluronic acid.

Designed to work at the cellular level, this therapy reduces inflammation and pain, enhances joint function, and helps preserve cartilage quality for patients with grade II and III knee osteoarthritis, Cipla said without providing the cost of the therapy. Current standard treatments primarily offer short-term relief through painkillers, viscosupplementation, or physiotherapy, often leaving a critical unmet need for therapies that target disease progression, Cipla said.

Cipla said more than 48.4 million people in India suffering with the knee osteoarthritis as of 2021.

Cipla's consolidated net profit for the September quarter rose 4% on year to INR 13.5 billion and revenue for the quarter was up 7.6% on year at INR 75.9 billion. On Wednesday, the company's shares ended at INR 1,508 on the National Stock Exchange, down 0.6% from their previous close.  End

Reported by Narayana Krishna

Edited by Akul Nishant Akhoury

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.